Phenotype of new daily persistent headache: subtypes and comparison to transformed chronic daily headache.

"Declarations Competing interestsS. Cheema is supported by a research fellowship sponsored by Abbott.A. Stubberud has received speaker honoraria from TEVA.K. Rantell reports no disclosures relevant to the manuscript.P. Nachev reports no disclosures relevant to the manuscript.E. Tronvik reports no disclosures relevant to the manuscript.M. Matharu is chair of the medical advisory board of the CSF Leak Association; has served on advisory boards for Allergan, Autonomic Technologies Inc, Eli Lilly, Novartis, Pfizer, Salvia and TEVA; has received payment for educational presentations from Allergan, electroCore, Eli Lilly, Novartis and TEVA; has received grants from Abbott, Medtronic and electroCore; and has a patent on system and method for diagnosing and treating headaches (WO2018051103A1, issued). Competing interests S. Cheema is supported by a research fellowship sponsored by Abbott. A. Stubberud has received speaker honoraria from TEVA. K. Rantell reports no disclosures relevant to the manuscript. P. Nachev reports no disclosures relevant to the manuscript. E. Tronvik reports no disclosures relevant to the manuscript. M. Matharu is chair of the medical advisory board of the CSF Leak Association; has served on advisory boards for Allergan, Autonomic Technologies Inc, Eli Lilly, Novartis, Pfizer, Salvia and TEVA; has received payment for educational presentations from Allergan, electroCore, Eli Lilly, Novartis and TEVA; has received grants from Abbott, Medtronic and electroCore; and has a patent on system and method for diagnosing and treating headaches (WO2018051103A1, issued)."

"Funding No funding received specifically for this study. PN is funded by the Wellcome Trust."